Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial

D Gaudet, D Pall, GF Watts, SJ Nicholls… - JAMA …, 2024 - jamanetwork.com
Importance Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic
cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis …

Precision Medicine Approaches to Vascular Disease: JACC Focus Seminar 2/5

CL Miller, AR Kontorovich, K Hao, L Ma… - Journal of the American …, 2021 - jacc.org
In this second of a 5-part Focus Seminar series, we focus on precision medicine in the
context of vascular disease. The most common vascular disease worldwide is …

[HTML][HTML] The impact of lipid-lowering medications on coronary artery plaque characteristics

VP Pulipati, FJ Alenghat - American Journal of Preventive Cardiology, 2021 - Elsevier
Atherosclerosis is the predominant cause of coronary artery disease. The last several
decades have witnessed significant advances in lipid-lowering therapies, which comprise a …

Increased cellular uptake of polyunsaturated fatty acids and phytosterols from natural micellar oil

C Röhrl, F Stübl, M Maier, B Schwarzinger… - Nutrients, 2020 - mdpi.com
The transport of hydrophobic compounds to recipient cells is a critical step in nutrient
supplementation. Here, we tested the effect of phospholipid-based emulsification on the …

[HTML][HTML] Recent updates in dyslipidemia management: perspectives in stroke-specific situation

WK Seo, MB Hosseini, OY Bang… - Precision and Future …, 2020 - pfmjournal.org
Managing dyslipidemia in stroke is essential. During the past several decades, monumental
changes in dyslipidemia management have occurred, resulting in improvement in outcomes …

A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy

Y Efremov, A Ermolaeva, G Vladimirov, S Gordleeva… - Plos one, 2022 - journals.plos.org
Cardiovascular diseases associated with high cholesterol (hypercholesterolemia) and low-
density lipoproteins (LDL) levels are significant contributors to total mortality in develo** …

Hipertrigliceridemia: clasificación, riesgo cardiovascular y conducta terapéutica

SNG Benítez, GEF Díaz, RCV Cabodevilla… - Correo Científico …, 2020 - revcocmed.sld.cu
La hipertrigliceridemia es una afección común, debida a alteraciones genéticas o primarias
y secundarias a enfermedades o medicamentos. Su causa principal es el estilo de vida no …

Nuevos enfoques terapéuticos de las dislipidemias

IO Armas, AE Lara, SNG Benítez… - … Científico Médico de …, 2020 - medigraphic.com
La dislipidemia es un factor de riesgo importante modificable de enfermedad cardiovascular
por aterosclerosis. Se realizó una revisión bibliográfica con los descriptores dislipidemia y …

[HTML][HTML] Hipertrigliceridemia: clasificación, riesgo cardiovascular y conducta terapéutica

SN González Benítez, GE Feria Díaz… - Correo Científico …, 2020 - scielo.sld.cu
La hipertrigliceridemia es una afección común, debida a alteraciones genéticas o primarias
y secundarias a enfermedades o medicamentos. Su causa principal es el estilo de vida no …

Novel therapeutics in hypertriglyceridaemia and chylomicronaemia

JDG Díaz - Medicina Clínica (English Edition), 2020 - Elsevier
Currently there is evidence on hypertriglyceridaemia as an independent risk factor of
atherosclerosis. Chylomicronaemia associated with very high concentration of triglycerides …